Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study reveals how long patients stay on secukinumab for skin and joint conditions

NCT ID NCT05155098

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study followed 127 adults with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis who were already taking or starting secukinumab. Researchers observed them for two years to see how long they continued the medication and how their quality of life changed. The goal was to gather real-world data on treatment patterns and effectiveness outside of a controlled clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this study could show how well secukinumab works in everyday practice, helping doctors and patients make more informed treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or lifestyle. It does not test a new treatment or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

127 people

The number who actually took part.

Started

Mar 2022

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent of the patient to participate in the study 2. Age 18-80 years. 3. Patients with an assured diagnosis by the treating physician of active moderate to severe plaque psoriasis or active PsA or active AS or active non-radiographic axial SpA. 4. Patients must have received the official approval to receive secukinumab in Dermatology Disease Prior Authorization (DDPA) or Rheumatology Disease Prior Authorization (RDPA) before study participation or the decision to treat patient's condition with secukinumab is happened before entering the study 5. Patients must receive the first dose of secukinumab during the study enrollment period. 6. Patients for whom the decision for a therapy with secukinumab is made by the attending treating physician, regardless of this non-interventional study. 7. Patients who have EQ-5D score before start the 1st dose secukinumab. Exclusion Criteria: 1. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from study participation for the 2 year study period.\* 2. Patients participating in parallel in other interventional clinical trial. 3. Patients participated in an interventional clinical trial with secukinumab involvement in the past. * Note: For example, patients diagnosed with a terminal illness and those with cognitive impairment due to dementia and Alzheimer's disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Non-Radiographic Axial Spondyloarthritis psoriasis psoriatic arthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankylosing spondylitis Moderate to severe plaque psoriasis Non-radiographic axial spondyloarthritis Psoriatic arthritis

Contacts and locations

Locations

  • Novartis Investigative Site

    Songkhla, Hat Yai, 90110, Thailand

  • Novartis Investigative Site

    Muang, Thailand, 12120, Thailand

  • Novartis Investigative Site

    Khon Kaen, THA, 40002, Thailand

  • Novartis Investigative Site

    Bangkok, 10300, Thailand

  • Novartis Investigative Site

    Bangkok, 10330, Thailand

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Bangkok, 10700, Thailand

  • Novartis Investigative Site

    Chiang Mai, 50200, Thailand

  • Novartis Investigative Site

    Kaen, 40000, Thailand

  • Novartis Investigative Site

    Nakhon Ratchasima, 30000, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.